Overview: Hepatitis B Virus e Antigen Antibody Panel
Introduction: The Hepatitis B Virus e Antigen Antibody Panel is a diagnostic tool designed to screen for HBeAg and HBeAb using serum samples. In India, HBeAg positivity indicates high infectivity and active replication (~20-30 percent of chronic HBV), while HBeAb seroconversion marks lower replication and better prognosis. High morbidity from under-testing in chronic HBV patients, limited labs, delayed monitoring leading to missed flares or HCC risk. Per microbiology/immunology practices aligned with ICMR and National Viral Hepatitis Control Programme guidelines, the test employs immunoassay for HBVeAg and HBVeAb over 1-2 days with high accuracy, valuable for assessing viral activity and treatment candidacy. This diagnostic falls under viral screening and targets chronic HBV patients for monitoring or pre-treatment evaluation, addressing accurate detection to guide antiviral initiation or surveillance. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise infectivity assessment and reducing HBV complications. Its serum-based approach ensures reliable serology.
Other Names: Hep Be Pnl.
FDA Status: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.
Historical Milestone: HBeAg/HBeAb standard; in India, used in HBV clinics.
Purpose: The test assesses 2 parameters including HBVeAg to guide hepatitis B viral screening, determine infectivity, inform therapy.
Test Parameters: 1. HBVeAg, 2. HBVeAb.
Pretest Condition: No fasting required; patients should have chronic HBV diagnosis.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on HBV duration, liver function, treatment.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected high infectivity including transmission, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or seroconversion phase can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive HBeAg indicates high replication; HBeAb positive suggests lower activity, necessitating specialist input.
Specialist Consultation: Hepatologists should be consulted for management.
Additional Supporting Tests: HBV DNA viral load for confirmation.
Test Limitations: Does not assess viral load; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, HBV Studies India 2023.
